# A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

> **NCT04349800** · PHASE1 · COMPLETED · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 84 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** KVD900
- **DRUG:** Placebo to KVD900

## Key facts

- **NCT ID:** NCT04349800
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-04
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04349800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04349800, "A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT04349800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*